Submission of Advertisement Clipping of the extract of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended 31st December, 2025
3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
3B BlackBio Dx has published the newspaper advertisement of its Q3 FY26 unaudited results approved by the Board on 6 February 2026. On a standalone basis, revenue rose to Rs 2,900.76 lakh in Q3 FY26 from Rs 2,644.03 lakh a year earlier, while net profit after tax grew to Rs 1,446.02 lakh from Rs 1,344.84 lakh. On a consolidated basis, the picture is much stronger: revenue nearly doubled to Rs 5,593.40 lakh in Q3 FY26 (vs Rs 2,840.55 lakh in Q3 FY25), and net profit after tax jumped to Rs 2,244.29 lakh from Rs 1,349.52 lakh. For the nine-month period, consolidated revenue rose to Rs 12,189.32 lakh (vs Rs 8,411.40 lakh) and consolidated net profit reached Rs 5,012.50 lakh (vs Rs 3,965.56 lakh). Statutory auditors issued an unmodified review conclusion, and the results are IND AS compliant.
The consolidated numbers show strong double-digit revenue and profit growth, driven largely by subsidiaries, suggesting the group is scaling well beyond the standalone business — likely positive for shareholders, though investors should compare these with segment trends and full-year guidance.